<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01869959</url>
  </required_header>
  <id_info>
    <org_study_id>12708</org_study_id>
    <secondary_id>I1K-MC-GLUG</secondary_id>
    <nct_id>NCT01869959</nct_id>
  </id_info>
  <brief_title>A Study of LY2405319 in Participants With Type 2 Diabetes</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2405319 With 28 Days of Subcutaneous Injections in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study was to evaluate the safety and tolerability of LY2405319. It
      was given as a daily injection under the skin to participants with type 2 diabetes mellitus
      (T2DM) for 28 days. This study determined how long the drug stays in the body and how it
      affects blood sugar levels. After screening, the study lasted about 2 months for each
      participant. Participants continued their prestudy regimen of diet and exercise alone or in
      combination with metformin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline through Day 56</time_frame>
    <description>The number of participants with 1 or more SAEs considered by the investigator to be related to study drug administration is reported. SAEs were classified using the Medical Dictionary for Regulatory Activities (MedDRA) 11.0. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 28 in Fasting Glucose</measure>
    <time_frame>Baseline, Day 28</time_frame>
    <description>Change from baseline to Day 28 in fasting blood glucose is presented. The predose fasting blood glucose measurement on Day 1 served as the baseline value. LS means were calculated using a linear mixed effects model with treatment, day, and treatment times day as fixed effects; baseline as covariate; and participant as a random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7 Point Self-monitored Blood Glucose (SMBG)</measure>
    <time_frame>Baseline (Day -5, -4, or -3) and Week 4 (Days 24, 25, or 26)</time_frame>
    <description>The daily mean of the 7-point SMBG values is presented. Seven-point glucose profiles were measured by participants at baseline and at Week 4. The 7-point SMBG mean on Days -5, -4, or -3 served as the baseline value; the 7-point SMBG mean on Days 24, 25, or 26 served as the Week 4 value. Blood glucose was measured before and 2 hours after each meal and at bedtime.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 4 in Glucose Area Under the Curve (AUC)</measure>
    <time_frame>Predose and 2 hours postdose (Baseline, Week 4)</time_frame>
    <description>Change from baseline to Week 4 in glucose AUC during an oral glucose tolerance test (OGTT) is presented. Blood samples were obtained prior to the glucose bolus to 2 hours after administration of the glucose bolus. The AUC measurement on Day -1 served as the baseline value. LS means were calculated using an analysis of covariance model with treatment as fixed effect and baseline as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 4 in Insulin Area Under the Curve (AUC)</measure>
    <time_frame>Predose and 2 hours postdose (Baseline, Week 4)</time_frame>
    <description>Change from baseline to Week 4 in insulin AUC during an OGTT is presented. Blood samples were obtained prior to the glucose bolus to 2 hours after administration of the glucose bolus. The AUC measurement on Day -1 served as the baseline value. LS means were calculated using an analysis of covariance model with treatment as fixed effect and baseline as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 4 in C-peptide Area Under the Curve (AUC)</measure>
    <time_frame>Predose and 2 hours postdose (Baseline, Week 4)</time_frame>
    <description>Change from baseline to Week 4 in C-peptide AUC during an OGTT is presented. Blood samples were obtained prior to the glucose bolus to 2 hours after administration of the glucose bolus. The AUC measurement on Day -1 served as the baseline value. LS means were calculated using an analysis of covariance model with treatment as a fixed effect and baseline as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 28 in Fasting Lipid Profile</measure>
    <time_frame>Baseline, Day 28</time_frame>
    <description>Change from baseline to Day 28 in fasting lipids, including cholesterol, low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), and triglycerides is presented. The predose measurement for each variable on Day 1 served as the baseline value. LS means were calculated using a linear mixed effects model with treatment, day, and treatment times day as fixed effects; baseline as covariate; and participant as a random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 28 in Body Weight</measure>
    <time_frame>Baseline, Day 28</time_frame>
    <description>Change from baseline to Day 28 in body weight is presented. The predose body weight measurement on Day 1 served as the baseline value. LS means were calculated using a linear mixed effects model with treatment, day, time, and treatment times time, treatment times day, and treatment times day times time were fixed effects; baseline as covariate; and participant as a random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 28 in Adiponectin</measure>
    <time_frame>Baseline, Day 28</time_frame>
    <description>Change from baseline to Day 28 in adiponectin is presented. The predose adiponectin measurement on Day 1 served as the baseline value. LS means were calculated using a linear mixed effects model with treatment, day, treatment times day as fixed effects, baseline as covariate, and participant as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 28 in C-Reactive Protein</measure>
    <time_frame>Baseline, Day 28</time_frame>
    <description>Change from baseline to Day 28 in C-reactive protein is presented. The predose C-reactive protein measurement on Day 1 served as the baseline value. LS means were calculated using a linear mixed effects model with treatment, day, and treatment times day as fixed effects; baseline as covariate; and participant as random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration Time Curve (AUC) of LY2405319</measure>
    <time_frame>Predose through Day 28 (48 hours postdose)</time_frame>
    <description>AUC for LY2405319 is presented. Data represent AUC for 1 dosing interval at steady state. Blood samples were collected predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, and 48 hours postdose on Day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum Concentration (Cmax) of LY2405319</measure>
    <time_frame>Predose through Day 28 (48 hours postdose)</time_frame>
    <description>Cmax of LY2405319 is presented. Blood samples were collected predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, and 48 hours postdose on Day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants With Anti-LY2405319 Antibodies</measure>
    <time_frame>Day 1 through Day 56</time_frame>
    <description>The number of participants that tested positive for anti-LY2405319 antibodies is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 28 in Eating Inventory for Cognitive Restraint of Eating, Disinhibition, and Hunger</measure>
    <time_frame>Baseline, Day 28</time_frame>
    <description>Change from baseline to Day 28 in Eating Inventory (EI) subscales are presented. The EI is a 51-item inventory that measures dietary restraint (the cognitive intention to restrict energy intake; scores range from 0 to 21), disinhibition (the tendency to episodically overeat, often in response to external cues; scores range from 0 to 16), and perceived hunger (scores range from 0 to 14). A low score indicates a low exhibition of behavior and a high score indicates a high exhibition of behavior. The measurement for each variable obtained on Day -2 served as the baseline value. LS means were calculated using an analysis of covariance model with treatment, day, and treatment times day as fixed effects, and baseline as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 28 in the Food Preference Questionnaire (FPQ) Score</measure>
    <time_frame>Baseline, Day 28</time_frame>
    <description>The table below represents the change from baseline in FPQ total score. The FPQ was administered to assess overall preference for foods of different macronutrient contents utilizing a macronutrient self-selection paradigm. Participants rated their preference on a range from 1 to 9 with 1 (dislike extremely) to 9 (like extremely) for a battery of 72 commonly consumed foods with fat content varying significantly in sugar, complex carbohydrates, and protein. The total score was calculated by averaging preference scores of 72 items. A low mean score of 1 to 9 scale indicate a low preference for the foods listed and a high mean score indicate a high preference for the foods listed. The FPQ measurement on Day -2 served as the baseline value. LS means were calculated using an analysis of covariance model with treatment, day, and treatment times day as fixed effects, and baseline as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 28 in The Patient Health Questionnaire (PHQ-9) Score</measure>
    <time_frame>Baseline, Day 28</time_frame>
    <description>Change from baseline to Day 28 in the PHQ-9 total score is presented. Participants were asked to score the severity of depressive symptoms over the last 2 weeks. Items were scored 0 (not at all), 1 (several days), 2 (half of the days), or 3 (nearly every day). The total PHQ-9 score is the sum of the score for each item and range from 0 to 27. A score of 0 means low depression severity and a score of 27 means high depression severity. Depression severity will be given a quality rating based on the total PHQ-9 score, as follows: None (0-4); Mild (5-9); Moderate (10-14); Moderately severe (15-19); and Severe (20-27). The PHQ-9 measurement obtained on Day -2 served as the baseline value. LS means were calculated using an analysis of covariance model with treatment, day, and treatment times day as fixed effects, and baseline as covariate.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo-matching LY2405319 injected subcutaneously (SC) once daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 mg LY2405319</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 3 milligrams (mg) LY2405319 injected SC once daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg LY2405319</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 10 mg LY2405319 injected SC once daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 mg LY2405319</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 20 mg LY2405319 injected SC once daily for 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2405319</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>3 mg LY2405319</arm_group_label>
    <arm_group_label>10 mg LY2405319</arm_group_label>
    <arm_group_label>20 mg LY2405319</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a diagnosis of T2DM.

          -  Are on diet and exercise or diet, exercise, and metformin (stable dose of at least
             1000 mg/day for at least 60 days) regimen.

          -  Have a glycosylated hemoglobin A1c (HbA1c) value of 7.0% to 10.0%, inclusive, or are
             on metformin and an additional oral antidiabetic medication (OAM) with an HbA1c value
             of 6.5% to 9.5%, inclusive.

          -  Participants on another OAM in addition to metformin therapy may be randomized if
             removed from treatment of the other OAM ≥14 days prior to study drug administration
             and fasting blood glucose is ≥145 mg per deciliter (mg/dL) and ≤270 mg/dL.

          -  Are females not of child-bearing potential due to surgical sterilization or are
             postmenopausal.

          -  Have a body mass index (BMI) ≥25 and ≤40.

          -  Have clinical laboratory test results within normal reference range for the
             population.

        Exclusion Criteria:

          -  Use insulin, thiazolidinediones (TZDs), dipeptidyl peptidase (DPP) IV inhibitors, or
             exenatide during the 3 months prior to screening.

          -  Have had more than 1 episode of severe hypoglycemia requiring assistance of another
             person to administer a resuscitative action within 6 months prior to entry into the
             study or are currently diagnosed with having hypoglycemia unawareness.

          -  Have had 2 or more emergency room visits or hospitalizations due to poor glucose
             control in the past 6 months.

          -  Have any abnormality of the electrocardiogram (ECG) that will, in the opinion of the
             investigator, impair the ability to measure the QT (a corrected QC [QTc] [Bazett's
             correction] interval &gt;450 milliseconds [msec] for men and &gt;470 msec for women or a PR
             interval &gt;220 msec are specifically excluded) or have conduction abnormalities that
             may confound the QTc analysis.

          -  Have a personal or family history of long QT syndrome, family history of sudden death,
             personal history of unexplained syncope within the last year; or use prescription or
             over-the-counter medications known to prolong the QT or QTc interval.

          -  Have diastolic blood pressure (DBP) ≥95 millimeters of mercury (mm Hg) and/or systolic
             blood pressure (SBP) ≥160 mm Hg.

          -  Have an active or untreated malignancy or have been in remission from a clinically
             significant malignancy for &lt;5 years.

          -  Have a history of a transplanted organ.

          -  Evidence of a significant active, uncontrolled endocrine or autoimmune abnormality, as
             judged by the investigator, at screening.

          -  Have a history of human immunodeficiency virus (HIV).

          -  Have a known allergy to yeast or yeast proteins, history of anaphylaxis with
             bronchospasm, or atopic dermatitis with chronic urticaria.

          -  Have any other condition (including known drug or alcohol abuse or psychiatric
             disorder within the last 6 months) that may preclude the participant from following
             and completing the protocol.

          -  Have a significant history of or current cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine (including pancreatitis), hematological, or neurological
             disorders capable of significantly altering the absorption, metabolism, or elimination
             of drugs; of constituting a risk when taking the study medication; or of interfering
             with the interpretation of data.

          -  Are women who are breastfeeding.

          -  Have had a significant change in weight, defined as a gain or loss of at least 4
             kilograms (kg) (9 pounds) in the 90 days prior to randomization.

          -  Have taken in the 30 days prior to randomization, a medication, herbal product, or
             nutritional supplement that affects adipose mass or distribution or energy balance.

          -  Are receiving chronic (&gt;2 weeks) systemic glucocorticoid therapy (excluding topical or
             inhaled preparations) or have received such therapy within 4 weeks immediately prior
             to second screening appointment.

          -  Have current or recent (within the past 3 months) use of gemfibrozil or fenofibrate,
             niacin, ezetimibe, or bile acid binding resins (for example, cholestyramines). Stable
             statin therapy of ≥3 months will be allowed.

          -  Are currently taking central nervous system (CNS) stimulant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Deland</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2013</study_first_submitted>
  <study_first_submitted_qc>May 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2013</study_first_posted>
  <results_first_submitted>October 27, 2016</results_first_submitted>
  <results_first_submitted_qc>January 27, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 20, 2017</results_first_posted>
  <last_update_submitted>January 27, 2017</last_update_submitted>
  <last_update_submitted_qc>January 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>3 mg LY2405319</title>
          <description>3 milligrams (mg) LY2405319 injected SC once daily for 28 days.</description>
        </group>
        <group group_id="P2">
          <title>10 mg LY2405319</title>
          <description>10 mg LY2405319 injected SC once daily for 28 days.</description>
        </group>
        <group group_id="P3">
          <title>20 mg LY2405319</title>
          <description>20 mg LY2405319 injected SC once daily for 28 days.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo-matching LY2405319 injected subcutaneously (SC) once daily for 28 days.</description>
        </group>
        <group group_id="P5">
          <title>All Randomized Participants</title>
          <description>All participants randomized in the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomization Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="46">One participant discontinued after randomization but did not receive study drug.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="0">Participants were randomized to treatment groups for the Treatment Period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants who received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>3 mg LY2405319</title>
          <description>3 mg LY2405319 injected SC once daily for 28 days.</description>
        </group>
        <group group_id="B2">
          <title>10 mg LY2405319</title>
          <description>10 mg LY2405319 injected SC once daily for 28 days.</description>
        </group>
        <group group_id="B3">
          <title>20 mg LY2405319</title>
          <description>20 mg LY2405319 injected SC once daily for 28 days.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo-matching LY2405319 injected subcutaneously (SC) once daily for 28 days.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.5" spread="7.3"/>
                    <measurement group_id="B2" value="59.6" spread="9.2"/>
                    <measurement group_id="B3" value="56.9" spread="10.2"/>
                    <measurement group_id="B4" value="58.6" spread="6.3"/>
                    <measurement group_id="B5" value="57.7" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</title>
        <description>The number of participants with 1 or more SAEs considered by the investigator to be related to study drug administration is reported. SAEs were classified using the Medical Dictionary for Regulatory Activities (MedDRA) 11.0. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
        <time_frame>Baseline through Day 56</time_frame>
        <population>All participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>3 mg LY2405319</title>
            <description>Participants received 3 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>10 mg LY2405319</title>
            <description>Participants received 10 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>20 mg LY2405319</title>
            <description>Participants received 20 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo-matching LY2405319 injected SC once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</title>
          <description>The number of participants with 1 or more SAEs considered by the investigator to be related to study drug administration is reported. SAEs were classified using the Medical Dictionary for Regulatory Activities (MedDRA) 11.0. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
          <population>All participants who received at least 1 dose of study drug.</population>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 28 in Fasting Glucose</title>
        <description>Change from baseline to Day 28 in fasting blood glucose is presented. The predose fasting blood glucose measurement on Day 1 served as the baseline value. LS means were calculated using a linear mixed effects model with treatment, day, and treatment times day as fixed effects; baseline as covariate; and participant as a random effect.</description>
        <time_frame>Baseline, Day 28</time_frame>
        <population>Participants who received at least 1 dose of study drug with evaluable blood glucose data.</population>
        <group_list>
          <group group_id="O1">
            <title>3 mg LY2405319</title>
            <description>Participants received 3 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>10 mg LY2405319</title>
            <description>Participants received 10 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>20 mg LY2405319</title>
            <description>Participants received 20 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo-matching LY2405319 injected SC once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 28 in Fasting Glucose</title>
          <description>Change from baseline to Day 28 in fasting blood glucose is presented. The predose fasting blood glucose measurement on Day 1 served as the baseline value. LS means were calculated using a linear mixed effects model with treatment, day, and treatment times day as fixed effects; baseline as covariate; and participant as a random effect.</description>
          <population>Participants who received at least 1 dose of study drug with evaluable blood glucose data.</population>
          <units>milligrams per deciliter (mg/dL)</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" lower_limit="-19.2" upper_limit="12.2"/>
                    <measurement group_id="O2" value="-6.7" lower_limit="-24.4" upper_limit="11.0"/>
                    <measurement group_id="O3" value="-10.5" lower_limit="-24.3" upper_limit="3.4"/>
                    <measurement group_id="O4" value="3.2" lower_limit="-14.1" upper_limit="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>7 Point Self-monitored Blood Glucose (SMBG)</title>
        <description>The daily mean of the 7-point SMBG values is presented. Seven-point glucose profiles were measured by participants at baseline and at Week 4. The 7-point SMBG mean on Days -5, -4, or -3 served as the baseline value; the 7-point SMBG mean on Days 24, 25, or 26 served as the Week 4 value. Blood glucose was measured before and 2 hours after each meal and at bedtime.</description>
        <time_frame>Baseline (Day -5, -4, or -3) and Week 4 (Days 24, 25, or 26)</time_frame>
        <population>All participants who received at least 1 dose of study drug with evaluable 7-Point SMBG data.</population>
        <group_list>
          <group group_id="O1">
            <title>3 mg LY2405319</title>
            <description>Participants received 3 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>10 mg LY2405319</title>
            <description>Participants received 10 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>20 mg LY2405319</title>
            <description>Participants received 20 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo-matching LY2405319 injected SC once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>7 Point Self-monitored Blood Glucose (SMBG)</title>
          <description>The daily mean of the 7-point SMBG values is presented. Seven-point glucose profiles were measured by participants at baseline and at Week 4. The 7-point SMBG mean on Days -5, -4, or -3 served as the baseline value; the 7-point SMBG mean on Days 24, 25, or 26 served as the Week 4 value. Blood glucose was measured before and 2 hours after each meal and at bedtime.</description>
          <population>All participants who received at least 1 dose of study drug with evaluable 7-Point SMBG data.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Days -6, -5, or -4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178.01" spread="5.95"/>
                    <measurement group_id="O2" value="171.13" spread="5.02"/>
                    <measurement group_id="O3" value="183.97" spread="4.19"/>
                    <measurement group_id="O4" value="172.46" spread="5.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (Days 24, 25, or 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171.03" spread="6.10"/>
                    <measurement group_id="O2" value="167.95" spread="8.09"/>
                    <measurement group_id="O3" value="188.52" spread="7.14"/>
                    <measurement group_id="O4" value="177.41" spread="7.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 4 in Glucose Area Under the Curve (AUC)</title>
        <description>Change from baseline to Week 4 in glucose AUC during an oral glucose tolerance test (OGTT) is presented. Blood samples were obtained prior to the glucose bolus to 2 hours after administration of the glucose bolus. The AUC measurement on Day -1 served as the baseline value. LS means were calculated using an analysis of covariance model with treatment as fixed effect and baseline as covariate.</description>
        <time_frame>Predose and 2 hours postdose (Baseline, Week 4)</time_frame>
        <population>All participants who received at least 1 dose of study drug with evaluable glucose AUC data.</population>
        <group_list>
          <group group_id="O1">
            <title>3 mg LY2405319</title>
            <description>Participants received 3 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>10 mg LY2405319</title>
            <description>Participants received 10 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>20 mg LY2405319</title>
            <description>Participants received 20 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo-matching LY2405319 injected SC once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 4 in Glucose Area Under the Curve (AUC)</title>
          <description>Change from baseline to Week 4 in glucose AUC during an oral glucose tolerance test (OGTT) is presented. Blood samples were obtained prior to the glucose bolus to 2 hours after administration of the glucose bolus. The AUC measurement on Day -1 served as the baseline value. LS means were calculated using an analysis of covariance model with treatment as fixed effect and baseline as covariate.</description>
          <population>All participants who received at least 1 dose of study drug with evaluable glucose AUC data.</population>
          <units>milligrams*hr per deciliter (mg*hr/dL)</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.89" lower_limit="-36.21" upper_limit="61.98"/>
                    <measurement group_id="O2" value="-8.46" lower_limit="-66.69" upper_limit="49.76"/>
                    <measurement group_id="O3" value="-3.22" lower_limit="-51.94" upper_limit="45.49"/>
                    <measurement group_id="O4" value="-28.13" lower_limit="-83.13" upper_limit="26.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 4 in Insulin Area Under the Curve (AUC)</title>
        <description>Change from baseline to Week 4 in insulin AUC during an OGTT is presented. Blood samples were obtained prior to the glucose bolus to 2 hours after administration of the glucose bolus. The AUC measurement on Day -1 served as the baseline value. LS means were calculated using an analysis of covariance model with treatment as fixed effect and baseline as covariate.</description>
        <time_frame>Predose and 2 hours postdose (Baseline, Week 4)</time_frame>
        <population>All participants who received at least 1 dose of study drug with evaluable insulin (AUC) data.</population>
        <group_list>
          <group group_id="O1">
            <title>3 mg LY2405319</title>
            <description>Participants received 3 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>10 mg LY2405319</title>
            <description>Participants received 10 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>20 mg LY2405319</title>
            <description>Participants received 20 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo-matching LY2405319 injected SC once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 4 in Insulin Area Under the Curve (AUC)</title>
          <description>Change from baseline to Week 4 in insulin AUC during an OGTT is presented. Blood samples were obtained prior to the glucose bolus to 2 hours after administration of the glucose bolus. The AUC measurement on Day -1 served as the baseline value. LS means were calculated using an analysis of covariance model with treatment as fixed effect and baseline as covariate.</description>
          <population>All participants who received at least 1 dose of study drug with evaluable insulin (AUC) data.</population>
          <units>micro International units*hour/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.07" lower_limit="-20.40" upper_limit="0.26"/>
                    <measurement group_id="O2" value="-10.37" lower_limit="-23.11" upper_limit="2.36"/>
                    <measurement group_id="O3" value="-15.66" lower_limit="-25.11" upper_limit="-6.21"/>
                    <measurement group_id="O4" value="-17.98" lower_limit="-29.54" upper_limit="-6.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 4 in C-peptide Area Under the Curve (AUC)</title>
        <description>Change from baseline to Week 4 in C-peptide AUC during an OGTT is presented. Blood samples were obtained prior to the glucose bolus to 2 hours after administration of the glucose bolus. The AUC measurement on Day -1 served as the baseline value. LS means were calculated using an analysis of covariance model with treatment as a fixed effect and baseline as covariate.</description>
        <time_frame>Predose and 2 hours postdose (Baseline, Week 4)</time_frame>
        <population>All participants who received at least 1 dose of study drug with evaluable C-peptide AUC data.</population>
        <group_list>
          <group group_id="O1">
            <title>3 mg LY2405319</title>
            <description>Participants received 3 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>10 mg LY2405319</title>
            <description>Participants received 10 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>20 mg LY2405319</title>
            <description>Participants received 20 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo-matching LY2405319 injected SC once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 4 in C-peptide Area Under the Curve (AUC)</title>
          <description>Change from baseline to Week 4 in C-peptide AUC during an OGTT is presented. Blood samples were obtained prior to the glucose bolus to 2 hours after administration of the glucose bolus. The AUC measurement on Day -1 served as the baseline value. LS means were calculated using an analysis of covariance model with treatment as a fixed effect and baseline as covariate.</description>
          <population>All participants who received at least 1 dose of study drug with evaluable C-peptide AUC data.</population>
          <units>nanograms*hours/milliliter (ng*hr/mL)</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.61" lower_limit="-1.58" upper_limit="0.36"/>
                    <measurement group_id="O2" value="0.07" lower_limit="-1.03" upper_limit="1.17"/>
                    <measurement group_id="O3" value="-1.39" lower_limit="-2.27" upper_limit="-0.51"/>
                    <measurement group_id="O4" value="-1.59" lower_limit="-2.66" upper_limit="-0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 28 in Fasting Lipid Profile</title>
        <description>Change from baseline to Day 28 in fasting lipids, including cholesterol, low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), and triglycerides is presented. The predose measurement for each variable on Day 1 served as the baseline value. LS means were calculated using a linear mixed effects model with treatment, day, and treatment times day as fixed effects; baseline as covariate; and participant as a random effect.</description>
        <time_frame>Baseline, Day 28</time_frame>
        <population>All participants who received at least 1 dose of study drug with evaluable fasting lipid (ie, cholesterol, LDL-C, HDL-C, and triglyceride) data.</population>
        <group_list>
          <group group_id="O1">
            <title>3 mg LY2405319</title>
            <description>Participants received 3 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>10 mg LY2405319</title>
            <description>Participants received 10 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>20 mg LY2405319</title>
            <description>Participants received 20 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo-matching LY2405319 injected SC once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 28 in Fasting Lipid Profile</title>
          <description>Change from baseline to Day 28 in fasting lipids, including cholesterol, low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), and triglycerides is presented. The predose measurement for each variable on Day 1 served as the baseline value. LS means were calculated using a linear mixed effects model with treatment, day, and treatment times day as fixed effects; baseline as covariate; and participant as a random effect.</description>
          <population>All participants who received at least 1 dose of study drug with evaluable fasting lipid (ie, cholesterol, LDL-C, HDL-C, and triglyceride) data.</population>
          <units>milligrams per deciliter (mg/dL)</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cholesterol (n=10, n=8, n=13, n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="-6.8" upper_limit="14.6"/>
                    <measurement group_id="O2" value="-32.5" lower_limit="-44.5" upper_limit="-20.6"/>
                    <measurement group_id="O3" value="-31.4" lower_limit="-40.7" upper_limit="-22.0"/>
                    <measurement group_id="O4" value="-1.3" lower_limit="-13.0" upper_limit="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C (n=10, n=8, n=13, n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-10.5" upper_limit="10.3"/>
                    <measurement group_id="O2" value="-26.8" lower_limit="-38.6" upper_limit="-14.9"/>
                    <measurement group_id="O3" value="-24.2" lower_limit="-33.3" upper_limit="-15.1"/>
                    <measurement group_id="O4" value="-0.8" lower_limit="-13.1" upper_limit="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C (n=10, n=8, n=13, n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" lower_limit="7.1" upper_limit="14.0"/>
                    <measurement group_id="O2" value="10.2" lower_limit="6.3" upper_limit="14.1"/>
                    <measurement group_id="O3" value="9.1" lower_limit="6.0" upper_limit="12.1"/>
                    <measurement group_id="O4" value="-0.8" lower_limit="-4.7" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides (n=10, n=8, n=13, n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.5" lower_limit="-62.9" upper_limit="-14.1"/>
                    <measurement group_id="O2" value="-81.0" lower_limit="-107.3" upper_limit="-54.8"/>
                    <measurement group_id="O3" value="-84.4" lower_limit="-105.0" upper_limit="-63.8"/>
                    <measurement group_id="O4" value="6.8" lower_limit="-21.2" upper_limit="34.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 28 in Body Weight</title>
        <description>Change from baseline to Day 28 in body weight is presented. The predose body weight measurement on Day 1 served as the baseline value. LS means were calculated using a linear mixed effects model with treatment, day, time, and treatment times time, treatment times day, and treatment times day times time were fixed effects; baseline as covariate; and participant as a random effect.</description>
        <time_frame>Baseline, Day 28</time_frame>
        <population>All participants who received at least 1 dose of study drug with evaluable body weight data.</population>
        <group_list>
          <group group_id="O1">
            <title>3 mg LY2405319</title>
            <description>Participants received 3 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>10 mg LY2405319</title>
            <description>Participants received 10 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>20 mg LY2405319</title>
            <description>Participants received 20 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo-matching LY2405319 injected SC once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 28 in Body Weight</title>
          <description>Change from baseline to Day 28 in body weight is presented. The predose body weight measurement on Day 1 served as the baseline value. LS means were calculated using a linear mixed effects model with treatment, day, time, and treatment times time, treatment times day, and treatment times day times time were fixed effects; baseline as covariate; and participant as a random effect.</description>
          <population>All participants who received at least 1 dose of study drug with evaluable body weight data.</population>
          <units>kilograms (kg)</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" lower_limit="-1.6" upper_limit="0.3"/>
                    <measurement group_id="O2" value="-1.8" lower_limit="-2.9" upper_limit="-0.6"/>
                    <measurement group_id="O3" value="-1.5" lower_limit="-2.3" upper_limit="-0.7"/>
                    <measurement group_id="O4" value="-0.2" lower_limit="-1.3" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 28 in Adiponectin</title>
        <description>Change from baseline to Day 28 in adiponectin is presented. The predose adiponectin measurement on Day 1 served as the baseline value. LS means were calculated using a linear mixed effects model with treatment, day, treatment times day as fixed effects, baseline as covariate, and participant as random effect.</description>
        <time_frame>Baseline, Day 28</time_frame>
        <population>All participants who received at least 1 dose of study drug with evaluable adiponectin data.</population>
        <group_list>
          <group group_id="O1">
            <title>3 mg LY2405319</title>
            <description>Participants received 3 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>10 mg LY2405319</title>
            <description>Participants received 10 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>20 mg LY2405319</title>
            <description>Participants received 20 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo-matching LY2405319 injected SC once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 28 in Adiponectin</title>
          <description>Change from baseline to Day 28 in adiponectin is presented. The predose adiponectin measurement on Day 1 served as the baseline value. LS means were calculated using a linear mixed effects model with treatment, day, treatment times day as fixed effects, baseline as covariate, and participant as random effect.</description>
          <population>All participants who received at least 1 dose of study drug with evaluable adiponectin data.</population>
          <units>nanograms per milliliter (ng/mL)</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1850.7" lower_limit="405.1" upper_limit="3296.3"/>
                    <measurement group_id="O2" value="2907.1" lower_limit="1289.1" upper_limit="4525.1"/>
                    <measurement group_id="O3" value="5648.6" lower_limit="4345.2" upper_limit="6952.1"/>
                    <measurement group_id="O4" value="458.3" lower_limit="-1165.1" upper_limit="2081.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 28 in C-Reactive Protein</title>
        <description>Change from baseline to Day 28 in C-reactive protein is presented. The predose C-reactive protein measurement on Day 1 served as the baseline value. LS means were calculated using a linear mixed effects model with treatment, day, and treatment times day as fixed effects; baseline as covariate; and participant as random effect.</description>
        <time_frame>Baseline, Day 28</time_frame>
        <population>All participants who received at least 1 dose of study drug with evaluable C-reactive protein data.</population>
        <group_list>
          <group group_id="O1">
            <title>3 mg LY2405319</title>
            <description>Participants received 3 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>10 mg LY2405319</title>
            <description>Participants received 10 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>20 mg LY2405319</title>
            <description>Participants received 20 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo-matching LY2405319 injected SC once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 28 in C-Reactive Protein</title>
          <description>Change from baseline to Day 28 in C-reactive protein is presented. The predose C-reactive protein measurement on Day 1 served as the baseline value. LS means were calculated using a linear mixed effects model with treatment, day, and treatment times day as fixed effects; baseline as covariate; and participant as random effect.</description>
          <population>All participants who received at least 1 dose of study drug with evaluable C-reactive protein data.</population>
          <units>milligrams per liter (mg/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" lower_limit="-2.5" upper_limit="1.3"/>
                    <measurement group_id="O2" value="0.3" lower_limit="-1.8" upper_limit="2.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-1.6" upper_limit="1.7"/>
                    <measurement group_id="O4" value="0.4" lower_limit="-1.8" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Area Under the Concentration Time Curve (AUC) of LY2405319</title>
        <description>AUC for LY2405319 is presented. Data represent AUC for 1 dosing interval at steady state. Blood samples were collected predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, and 48 hours postdose on Day 28.</description>
        <time_frame>Predose through Day 28 (48 hours postdose)</time_frame>
        <population>All participants who received at least 1 dose of study drug with evaluable AUC of LY2405319 data.</population>
        <group_list>
          <group group_id="O1">
            <title>3 mg LY2405319</title>
            <description>Participants received 3 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>10 mg LY2405319</title>
            <description>Participants received 10 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>20 mg LY2405319</title>
            <description>Participants received 20 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Area Under the Concentration Time Curve (AUC) of LY2405319</title>
          <description>AUC for LY2405319 is presented. Data represent AUC for 1 dosing interval at steady state. Blood samples were collected predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, and 48 hours postdose on Day 28.</description>
          <population>All participants who received at least 1 dose of study drug with evaluable AUC of LY2405319 data.</population>
          <units>nanograms*hours/milliliter (ng*hr/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="409" spread="26.0"/>
                    <measurement group_id="O2" value="1520" spread="38.9"/>
                    <measurement group_id="O3" value="3410" spread="35.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Maximum Concentration (Cmax) of LY2405319</title>
        <description>Cmax of LY2405319 is presented. Blood samples were collected predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, and 48 hours postdose on Day 28.</description>
        <time_frame>Predose through Day 28 (48 hours postdose)</time_frame>
        <population>All participants who received at least 1 dose of study drug with evaluable Cmax of LY2405319 data.</population>
        <group_list>
          <group group_id="O1">
            <title>3 mg LY2405319</title>
            <description>Participants received 3 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>10 mg LY2405319</title>
            <description>Participants received 10 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>20 mg LY2405319</title>
            <description>Participants received 20 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Maximum Concentration (Cmax) of LY2405319</title>
          <description>Cmax of LY2405319 is presented. Blood samples were collected predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, and 48 hours postdose on Day 28.</description>
          <population>All participants who received at least 1 dose of study drug with evaluable Cmax of LY2405319 data.</population>
          <units>nanograms per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.9" spread="34.7"/>
                    <measurement group_id="O2" value="105" spread="62.9"/>
                    <measurement group_id="O3" value="247" spread="58.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants With Anti-LY2405319 Antibodies</title>
        <description>The number of participants that tested positive for anti-LY2405319 antibodies is presented.</description>
        <time_frame>Day 1 through Day 56</time_frame>
        <population>All participants who received at least 1 dose of study drug with evaluable anti-LY2405319 antibody data.</population>
        <group_list>
          <group group_id="O1">
            <title>3 mg LY2405319</title>
            <description>Participants received 3 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>10 mg LY2405319</title>
            <description>Participants received 10 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>20 mg LY2405319</title>
            <description>Participants received 20 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo-matching LY2405319 injected SC once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants With Anti-LY2405319 Antibodies</title>
          <description>The number of participants that tested positive for anti-LY2405319 antibodies is presented.</description>
          <population>All participants who received at least 1 dose of study drug with evaluable anti-LY2405319 antibody data.</population>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 28 in Eating Inventory for Cognitive Restraint of Eating, Disinhibition, and Hunger</title>
        <description>Change from baseline to Day 28 in Eating Inventory (EI) subscales are presented. The EI is a 51-item inventory that measures dietary restraint (the cognitive intention to restrict energy intake; scores range from 0 to 21), disinhibition (the tendency to episodically overeat, often in response to external cues; scores range from 0 to 16), and perceived hunger (scores range from 0 to 14). A low score indicates a low exhibition of behavior and a high score indicates a high exhibition of behavior. The measurement for each variable obtained on Day -2 served as the baseline value. LS means were calculated using an analysis of covariance model with treatment, day, and treatment times day as fixed effects, and baseline as covariate.</description>
        <time_frame>Baseline, Day 28</time_frame>
        <population>All participants who received at least 1 dose of study drug with evaluable EI data.</population>
        <group_list>
          <group group_id="O1">
            <title>3 mg LY2405319</title>
            <description>Participants received 3 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>10 mg LY2405319</title>
            <description>Participants received 10 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>20 mg LY2405319</title>
            <description>Participants received 20 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo-matching LY2405319 injected SC once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 28 in Eating Inventory for Cognitive Restraint of Eating, Disinhibition, and Hunger</title>
          <description>Change from baseline to Day 28 in Eating Inventory (EI) subscales are presented. The EI is a 51-item inventory that measures dietary restraint (the cognitive intention to restrict energy intake; scores range from 0 to 21), disinhibition (the tendency to episodically overeat, often in response to external cues; scores range from 0 to 16), and perceived hunger (scores range from 0 to 14). A low score indicates a low exhibition of behavior and a high score indicates a high exhibition of behavior. The measurement for each variable obtained on Day -2 served as the baseline value. LS means were calculated using an analysis of covariance model with treatment, day, and treatment times day as fixed effects, and baseline as covariate.</description>
          <population>All participants who received at least 1 dose of study drug with evaluable EI data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cognitive restraint of eating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.10" lower_limit="-2.68" upper_limit="0.48"/>
                    <measurement group_id="O2" value="-0.35" lower_limit="-2.09" upper_limit="1.39"/>
                    <measurement group_id="O3" value="-0.27" lower_limit="-1.71" upper_limit="1.17"/>
                    <measurement group_id="O4" value="-2.99" lower_limit="-4.73" upper_limit="-1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disinhibition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" lower_limit="-0.67" upper_limit="1.34"/>
                    <measurement group_id="O2" value="0.04" lower_limit="-1.06" upper_limit="1.15"/>
                    <measurement group_id="O3" value="-1.59" lower_limit="-2.47" upper_limit="-0.70"/>
                    <measurement group_id="O4" value="0.04" lower_limit="-1.06" upper_limit="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hunger</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="-0.32" upper_limit="2.32"/>
                    <measurement group_id="O2" value="2.05" lower_limit="0.59" upper_limit="3.50"/>
                    <measurement group_id="O3" value="0.53" lower_limit="-0.65" upper_limit="1.70"/>
                    <measurement group_id="O4" value="0.29" lower_limit="-1.16" upper_limit="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 28 in the Food Preference Questionnaire (FPQ) Score</title>
        <description>The table below represents the change from baseline in FPQ total score. The FPQ was administered to assess overall preference for foods of different macronutrient contents utilizing a macronutrient self-selection paradigm. Participants rated their preference on a range from 1 to 9 with 1 (dislike extremely) to 9 (like extremely) for a battery of 72 commonly consumed foods with fat content varying significantly in sugar, complex carbohydrates, and protein. The total score was calculated by averaging preference scores of 72 items. A low mean score of 1 to 9 scale indicate a low preference for the foods listed and a high mean score indicate a high preference for the foods listed. The FPQ measurement on Day -2 served as the baseline value. LS means were calculated using an analysis of covariance model with treatment, day, and treatment times day as fixed effects, and baseline as covariate.</description>
        <time_frame>Baseline, Day 28</time_frame>
        <population>All participants who received at least 1 dose of study drug with evaluable FPQ data.</population>
        <group_list>
          <group group_id="O1">
            <title>3 mg LY2405319</title>
            <description>Participants received 3 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>10 mg LY2405319</title>
            <description>Participants received 10 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>20 mg LY2405319</title>
            <description>Participants received 20 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo-matching LY2405319 injected SC once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 28 in the Food Preference Questionnaire (FPQ) Score</title>
          <description>The table below represents the change from baseline in FPQ total score. The FPQ was administered to assess overall preference for foods of different macronutrient contents utilizing a macronutrient self-selection paradigm. Participants rated their preference on a range from 1 to 9 with 1 (dislike extremely) to 9 (like extremely) for a battery of 72 commonly consumed foods with fat content varying significantly in sugar, complex carbohydrates, and protein. The total score was calculated by averaging preference scores of 72 items. A low mean score of 1 to 9 scale indicate a low preference for the foods listed and a high mean score indicate a high preference for the foods listed. The FPQ measurement on Day -2 served as the baseline value. LS means were calculated using an analysis of covariance model with treatment, day, and treatment times day as fixed effects, and baseline as covariate.</description>
          <population>All participants who received at least 1 dose of study drug with evaluable FPQ data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" lower_limit="-0.73" upper_limit="0.61"/>
                    <measurement group_id="O2" value="-0.43" lower_limit="-1.15" upper_limit="0.29"/>
                    <measurement group_id="O3" value="-0.77" lower_limit="-1.30" upper_limit="-0.24"/>
                    <measurement group_id="O4" value="0.74" lower_limit="0.09" upper_limit="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 28 in The Patient Health Questionnaire (PHQ-9) Score</title>
        <description>Change from baseline to Day 28 in the PHQ-9 total score is presented. Participants were asked to score the severity of depressive symptoms over the last 2 weeks. Items were scored 0 (not at all), 1 (several days), 2 (half of the days), or 3 (nearly every day). The total PHQ-9 score is the sum of the score for each item and range from 0 to 27. A score of 0 means low depression severity and a score of 27 means high depression severity. Depression severity will be given a quality rating based on the total PHQ-9 score, as follows: None (0-4); Mild (5-9); Moderate (10-14); Moderately severe (15-19); and Severe (20-27). The PHQ-9 measurement obtained on Day -2 served as the baseline value. LS means were calculated using an analysis of covariance model with treatment, day, and treatment times day as fixed effects, and baseline as covariate.</description>
        <time_frame>Baseline, Day 28</time_frame>
        <population>All participants who received at least 1 dose of study drug with evaluable PHQ-9 data.</population>
        <group_list>
          <group group_id="O1">
            <title>3 mg LY2405319</title>
            <description>Participants received 3 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>10 mg LY2405319</title>
            <description>Participants received 10 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>20 mg LY2405319</title>
            <description>Participants received 20 mg LY2405319 injected SC once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo-matching LY2405319 injected SC once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 28 in The Patient Health Questionnaire (PHQ-9) Score</title>
          <description>Change from baseline to Day 28 in the PHQ-9 total score is presented. Participants were asked to score the severity of depressive symptoms over the last 2 weeks. Items were scored 0 (not at all), 1 (several days), 2 (half of the days), or 3 (nearly every day). The total PHQ-9 score is the sum of the score for each item and range from 0 to 27. A score of 0 means low depression severity and a score of 27 means high depression severity. Depression severity will be given a quality rating based on the total PHQ-9 score, as follows: None (0-4); Mild (5-9); Moderate (10-14); Moderately severe (15-19); and Severe (20-27). The PHQ-9 measurement obtained on Day -2 served as the baseline value. LS means were calculated using an analysis of covariance model with treatment, day, and treatment times day as fixed effects, and baseline as covariate.</description>
          <population>All participants who received at least 1 dose of study drug with evaluable PHQ-9 data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26" lower_limit="-0.71" upper_limit="3.24"/>
                    <measurement group_id="O2" value="-0.50" lower_limit="-2.83" upper_limit="1.82"/>
                    <measurement group_id="O3" value="1.82" lower_limit="0.08" upper_limit="3.56"/>
                    <measurement group_id="O4" value="2.57" lower_limit="0.43" upper_limit="4.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>3 mg LY2405319</title>
          <description>Participants received 3 mg LY2405319 injected SC once daily for 28 days.</description>
        </group>
        <group group_id="E2">
          <title>10 mg LY2405319</title>
          <description>Participants received 10 mg LY2405319 injected SC once daily for 28 days.</description>
        </group>
        <group group_id="E3">
          <title>20 mg LY2405319</title>
          <description>Participants received 20 mg LY2405319 injected SC once daily for 28 days.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Participants received placebo-matching LY2405319 injected SC once daily for 28 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Optic ischaemic neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="39" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E3" events="46" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E3" events="11" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E4" events="6" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection site inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection site irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection site urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Scratch</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood calcium increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

